PR Newswire BiotechnologyQwen · 实盘不做把握 2/10不做原因:证据不足🔁 +1 同一事件
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:01:38 +1m38s·⚡ 决策 08-26 20:54:24 +52m46s·62.4 天前
义翘神州子公司SignalChem获Monod Bio AI蛋白质设计技术非独占许可，公司自述对业绩无重大影响
公司公告自身免责声明明确表示该业务收入不会对公司整体财务表现产生重大影响；未披露任何财务条款；非独占许可仅限研究用途；属于生命科学工具公司日常小型技术引进，不构成对130亿市值公司的可交易催化。
📄 原文PR Newswire Biotechnology↗ 原文
SEATTLE and RICHMOND, BC, Aug. 26, 2026 /PRNewswire/ -- Monod Bio, a Seattle-based AI-enabled protein design company, a…
不做 义翘神州（301047.SZ）
公司自身免责声明明确表示该业务收入不会对公司整体财务表现产生重大影响；未披露任何财务条款（无首付款/里程碑/特许权使用费）；非独占许可仅限研究用途；对130亿市值公司不构成可交易催化。近20日已因CRO主题涨56%后正在回调，无新增边际催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Monod Bio向义翘神州子公司SignalChem授予AI蛋白质设计技术非独占许可。关键判据：①公司自身免责声明明确表示'不会对公司整体财务表现产生重大影响'；②未披露首付款、里程碑或任何财务条款；③非独占、仅限研究用途；④义翘神州当前市值约130亿元，该等小型技术许可对收入/利润贡献可忽略。近20日股价已因CRO主题上涨56%后正在回调，本次事件无法提供新增边际催化。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:先例搜索未执行，因为公司自述无重大财务影响且未披露任何财务条款，事件不满足可交易催化的最低门槛，先例无法改变这一结论
方向:不适用——事件自身重要性不足，无需先例校准
涨幅量级:不适用
形态:不适用
工具调用 · 历史记录,结果未知(4 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- search_case_library · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 2,780 字
SEATTLE and RICHMOND, BC, Aug. 26, 2026 /PRNewswire/ -- Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies.
Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. The collaboration expands SignalChem's specialized CRO capabilities and supports Sino Biological's broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio.
"This agreement and the corresponding licensed technology strengthen our ability to help customers obtain high-quality discovery candidates more rapidly and address complex biological questions," said Dr. Rob Burgess, Chief Business Officer of Sino Biological.
Monod Bio's LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins engineered for high-performance recognition of various targets.
"SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base," said Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio. "This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
ABOUT SINO BIOLOGICAL & SIGNALCHEM BIOTECH:
SignalChem Biotech, a wholly owned subsidiary of Sino Biological Inc. (SZSE: 301047), provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America and Europe. For more information, visit www.sinobiological.com.
Disclaimer: The development of the related business may be affected by various factors, including changes in market demand. Given the company's broad product portfolio, the revenue associated with this business is not expected to have a material impact on the company's overall financial performance.
ABOUT MONOD BIO:
Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors and other functional proteins for research and diagnostic applications. Through its Monod Inside model, Monod Bio partners with life science companies to integrate its technologies into next-generation products and services. For more information, visit monod.bio.
SOURCE Monod Bio
Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. The collaboration expands SignalChem's specialized CRO capabilities and supports Sino Biological's broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio.
"This agreement and the corresponding licensed technology strengthen our ability to help customers obtain high-quality discovery candidates more rapidly and address complex biological questions," said Dr. Rob Burgess, Chief Business Officer of Sino Biological.
Monod Bio's LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins engineered for high-performance recognition of various targets.
"SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base," said Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio. "This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
ABOUT SINO BIOLOGICAL & SIGNALCHEM BIOTECH:
SignalChem Biotech, a wholly owned subsidiary of Sino Biological Inc. (SZSE: 301047), provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America and Europe. For more information, visit www.sinobiological.com.
Disclaimer: The development of the related business may be affected by various factors, including changes in market demand. Given the company's broad product portfolio, the revenue associated with this business is not expected to have a material impact on the company's overall financial performance.
ABOUT MONOD BIO:
Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors and other functional proteins for research and diagnostic applications. Through its Monod Inside model, Monod Bio partners with life science companies to integrate its technologies into next-generation products and services. For more information, visit monod.bio.
SOURCE Monod Bio
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。